View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 2, 2022

Veru, Lilly partner for Phase III second-line breast cancer trial

The Phase III trial will enrol 186 breast cancer patients to assess the safety and efficacy of enobosarm plus Verzenio.

Veru and Eli Lilly have signed a clinical trial partnership and supply agreement to analyse enobosarm plus Verzenio (abemaciclib) in Phase III ENABLAR-2 clinical trial to treat AR+ER+HER2- metastatic breast cancer.

An oral, new chemical entity and selective androgen receptor (AR) of Veru, enobosarm acts on the agonist that stimulates the AR, a suppressor of the tumour. 

Lilly’s Verzenio is a non-chemotherapy oral tablet and an inhibitor of cyclin-dependent kinase 4/6 (CDK4/6).

As per the deal, Veru will carry out the study while Lilly will be in charge of the Verzenio supply needed for the trial. 

Furthermore, Veru holds complete exclusive, worldwide rights to enobosarm.

Through the partnership, the companies will assess the safety and efficacy of 9mg oral doses of enobosarm given daily plus Verzenio versus active control in second-line treatment of AR+ ER+ HER2- metastatic breast cancer.

The multicentre, open-label, randomised, active control trial will enrol 186 individuals with metastatic AR+ ER+ HER2- breast cancer, who had earlier been given an estrogen-blocking agent plus palbociclib. 

Anticipated to start during the first quarter of this year, the trial will be carried out in nearly 35 trial centres in the US.

Median radiographic progression-free survival will be the primary efficacy endpoint of the trial.

Overall response rate, variation in short physical performance battery and change in DEXA-body composition muscle and bone will be included as the secondary endpoints.

Veru chairman, president and CEO Mitchell Steiner said: “Independently conducted proof of concept preclinical studies in human breast cancer models have demonstrated that the combination of enobosarm with a CDK4/6 inhibitor had greater antitumor synergistic activity in tumour samples from patients who had breast cancer progression following treatment with palbociclib, a CDK4/6 inhibitor, and an estrogen-blocking agent.”

In March last year, Lilly reported positive patient-reported outcomes from a trial that analysed the efficacy of Verzenio to treat high-risk early breast cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena